English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Polycystic ovary syndrome (PCOS) is a genetic condition highly associated with infertility in women. The increased uterine smooth muscle contractility plays a role in the PCOS pathogenesis. Studies have demonstrated the inhibitory effect of MK 571, a multidrug resistance protein inhibitor in the prostate, bladder and urethra contractility. However, no previous study has focused on the effects of MK 571 in the uterine contractions. Therefore, the aim of the present study is to evaluate the in vitro effects of MK 571 on uterine smooth muscle contractility in female rats. We have shown for the first time that MK 571 (20 µM) associated with isoproterenol (a non-selective β-adrenoceptor agonist, 10 µM) produced an inhibitory effect on uterine tissue contractility. More experimental and clinical studies are needed to elucidate the mechanism of action, as well as the safety and efficacy of MK 571 under pathological conditions in animals and humans.

MK 571, a multidrug resistance protein inhibitor, reduces uterus smooth muscle contractility in rats